Byondis is an independent, Dutch clinical-stage biopharmaceutical company committed to the development of innovative precision medicines targeting cancer and autoimmune diseases. Leveraging its proprietary linker-drug (LD) platform, GlycoConnect™, and its site-specific conjugation technology, Byondis creates next-generation antibody-drug conjugates (ADCs) and monoclonal antibodies. The company's pipeline features promising candidates, including its lead ADC [vic-]trastuzumab duocarmazine (SYD985), aimed at treating hard-to-treat cancers. Byondis focuses on translating novel scientific insights into therapies that address significant unmet medical needs and improve patient lives.
The Nijmegen headquarters serves as the central hub for all of Byondis's core operations, including research and development, clinical trial management, cGMP manufacturing of biopharmaceuticals, and corporate functions.
Located within the Noviotech Campus, the headquarters boasts state-of-the-art R&D laboratories, advanced biopharmaceutical manufacturing facilities compliant with cGMP standards, and modern office spaces designed to foster innovation and collaboration.
Byondis fosters a work culture centered on scientific excellence, innovation, collaboration, and a strong patient-first mentality. Employees are encouraged to be agile, proactive, and contribute to a shared mission of developing life-changing treatments.
The headquarters is strategically vital, concentrating Byondis's scientific expertise, technological platforms, and manufacturing capabilities, enabling the seamless progression of drug candidates from discovery through clinical development and towards potential commercialization.
While its core R&D and manufacturing are centralized in Nijmegen, The Netherlands, Byondis has a global operational footprint. This is primarily driven by its international clinical trials conducted across Europe, North America, and other regions. The company's U.S. office in San Diego, CA, further supports its global activities, particularly in clinical development and regulatory interactions. Byondis collaborates with international research institutions, contract research organizations (CROs), and partners to advance its pipeline worldwide.
Microweg 22
Nijmegen
Gelderland
The Netherlands
Address: Specific address not publicly listed; functions as a strategic presence.
To strengthen Byondis's operational capabilities and strategic partnerships in the key U.S. market, enhancing the global reach of its clinical programs and research initiatives.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Byondis' leadership includes:
Byondis has been backed by several prominent investors over the years, including:
Over the past year, Byondis has experienced key leadership transitions, including the appointment of Marco Timmers as permanent CEO, and strengthening its executive team with new appointments for Chief Business Officer and Chief Medical Officer to guide its strategic growth and pipeline advancement.
Discover the tools Byondis uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Byondis likely utilizes a common professional email format for its employees. Based on industry standards for companies of its size and nature, the most probable format is [firstinitial][lastname]@byondis.com or [first].[lastname]@byondis.com. Publicly available contact emails include generic addresses like info@byondis.com.
[first].[last]@byondis.com
Format
marco.timmers@byondis.com
Example
75%
Success rate
Byondis.com • April 22, 2024
Byondis shared promising preclinical results for its bispecific antibody BYBA-029 at the AACR Annual Meeting 2024. The data indicated significant anti-tumor effects in acute myeloid leukemia (AML) models, highlighting its potential as a novel therapeutic agent for AML....more
Byondis.com • December 7, 2023
Byondis announced encouraging Phase I trial data for its ADC, BYON4228, which targets CTLA-4 in patients with various solid tumors. Presented at the ESMO Immuno-Oncology Congress 2023, the findings showed good tolerability and early signals of anti-tumor activity....more
Byondis.com • September 5, 2023
Byondis announced the appointment of Marco Timmers, Ph.D., as its new Chief Executive Officer and Mark Gitzinger, Ph.D., MBA, as its new Chief Business Officer, strengthening its leadership team....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Byondis, are just a search away.